Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6514963
Methods for the inhibition of egg production in trematodes
expired -
US 6514948
Method for enhancing an immune response
expired -
US 6514942
Methods and compositions for stimulating T-lymphocytes
expired -
US 6514727
Antimicrobial theta defensins and methods of using same
expired -
US 6514701
Antimicrobial peptides and methods of use thereof
expired -
US 6514695
Compositions and methods for intraductal gene therapy
expired -
US 6514745
Oncoprotein protein kinase
expired -
US 6514697
Methods for detection of Crytosporidium species and isolates and for diagnosis of Cryptosporidium infections
expired -
US 6511811
Protein kinase C antagonist related to insulin receptor
expired -
US 6511847
Recombinant p53 adenovirus methods and compositions
expired -
US 6512097
High affinity human antibodies to tumor antigens
expired -
US 6512091
Genetic Markers for breast, ovarian, and prostatic cancer
expired -
US 6512004
Promoters of neural regeneration
expired -
US 6509317
Method of treating chronic cardiac disease
expired -
US 6509318
TGF-B inhibitors and methods
expired -
US 6509515
Transgenic mice expressing mutant human APP and forming congo red staining plaques
expired -
US 6509319
EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
expired -
US 6509444
Serum amyloid a isoform from colostrum
expired -
US 6506803
Methods of preventing and treating microbial infections
expired -
US 6506382
Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
expired -
US 6503498
Apolipoprotein A-1 adenovirus vector compositions and methods
expired -
US 6503914
Thienopyrimidine-based inhibitors of the Src family
expired -
US 6503915
Composition and method for treatment of cerebral ischemia
expired -
US 6503916
Treatment of ischemic brain injury
expired -
US 6500937
Nucleotide sequence encoding a mammary cell growth inhibitor
expired -
US 6500108
Radiation delivery system and method
expired -
US 6500798
Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators
expired -
US 6500539
Anti-adhesion cellulose acetate wound dressing
expired -
US 6500640
Nucleic acid molecules encoding modified dorsal tissue affecting factor
expired -
US 6500834
Composition and method for treatment of cerebral ischemia
expired -
US 6497902
Ionically crosslinked hydrogels with adjustable gelation time
expired -
US 6498189
Method for induction of L-selectin shedding
expired -
US 6498008
Method for detecting swine infertility and respiratory virus
expired -
US 6497877
Plasminogen activator as an anti-inflammatory agent
expired -
US 6498148
Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype
expired -
US 6495588
Scytonemin and methods of using thereof
expired -
US 6495586
Scytonemin and methods of using thereof
expired -
US 6495322
RAIDD, a novel death adaptor molecule
expired -
US 6492504
Nucleotide sequence of mammastatin and methods of use
expired -
US 6492104
EIA test using nondenatured HIV antigen for early detection of HIV infection
expired -
US 6492498
Multimeric immunotoxins
expired -
US 6492328
Novispirins: antimicrobial peptides
expired -
US 6492152
Core 1 &bgr;3-galactosyl transferases and methods of use thereof
expired -
US 6491906
CXC chemokines as regulators of angiogenesis
expired -
US 6489165
Chondrocyte-like cells useful for tissue engineering and methods
expired -
US 6489134
Kinesin motor modulators derived from the marine sponge Adocia
expired -
US 6489308
Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
expired -
US 6489144
Methods for enhancing the production of interferon in cell culture
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory